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Abstract Nonlinear mixed effects models parameters are
commonly estimated using maximum likelihood. The
properties of these estimators depend on the assumption
that residual errors are independent and normally dis-
tributed with mean zero and correctly defined variance.
Violations of this assumption can cause bias in parameter
estimates, invalidate the likelihood ratio test and preclude
simulation of real-life like data. The choice of error model
is mostly done on a case-by-case basis from a limited set of
commonly used models. In this work, two strategies are
proposed to extend and unify residual error modeling: a
dynamic transform-both-sides approach combined with a
power error model (dTBS) capable of handling skewed
and/or heteroscedastic residuals, and a t-distributed resid-
ual error model allowing for symmetric heavy tails. Ten
published pharmacokinetic and pharmacodynamic models
as well as stochastic simulation and estimation were used
to evaluate the two approaches. dTBS always led to sig-
nificant improvements in objective function value, with
most examples displaying some degree of right-skewness
and variances proportional to predictions raised to powers
between 0 and 1. The t-distribution led to significant
improvement for 5 out of 10 models with degrees of
freedom between 3 and 9. Six models were most improved
by the t-distribution while four models benefited more from
dTBS. Changes in other model parameter estimates were
observed. In conclusion, the use of dTBS and/or t-distri-
bution models provides a flexible and easy-to-use frame-
work capable of characterizing all commonly encountered
residual error distributions.
Keywords Residual error  Transform-both-sides 
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Introduction
Population modeling is increasingly used to analyze data
arising from clinical trials. Nonlinear mixed effects models
(NLMEM) enable simultaneous analysis of data gathered
from all study patients with the aim of determining an
underlying structural model driving the observations as
well as characterizing inter-individual variability (IIV),
which explains why different individuals can show differ-
ent responses to a given drug. In most cases, some infor-
mation is available beforehand about the structural model
based on the knowledge on the underlying system. For
example, models of different systems which have been
developed in multiple disease areas [1, 2] can be applied
and adapted to new drug entities. Information about IIV
can also be available in terms of physiological features of
the study population such as polymorphism in metabolic
enzymes or age-related alterations of particular organs.
Another layer of variability, typically referred to as resid-
ual unexplained variability (RUV), accounts for all
remaining variability which is not explained by the struc-
tural or parameter-variability model parts. This RUV arises
for example from physiological intra-individual variation,
assay error, errors in independent variables and model
misspecification. The residual error thus aggregates mul-
tiple processes which causes and consequences are poorly
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defined. Despite this complexity, in the modeling process
RUV is assumed to be normally distributed with mean zero
and a defined variance, which can be homoscedastic, i.e.,
constant over model predictions, or heteroscedastic, i.e.,
dependent on model predictions.
Misspecifications of the residual error model impact
both the estimation of and the simulation from NLMEM.
Let us considerer first the impact of a misspecification of
the scedasticity. Maximum likelihood (ML) estimation
utilizes the expected variance of the modeled outcome in
order to compute the likelihood to maximize. Estimation of
model parameters will thus depend on the residual variance
model, and parameter estimates may be biased if the wrong
variance model is chosen [3]. Inference using the computed
likelihood or standard errors (SEs) of parameter estimates
resulting from such a fit may also be invalidated [4, 5].
Despite these risks, testing for heteroscedasticity in
NLMEM is often limited to a plot of residuals or alterna-
tively their absolute or squared values versus model pre-
dictions. More advanced tests including the family of score
tests [6] have been proposed in fields such as econometrics
but have not penetrated the field of pharmacometrics.
When simulating from a NLMEM, predictions will clearly
depend on the defined relationship between residuals and
predictions, which is particularly important when simulat-
ing data outside of the range of the data used for estima-
tion. The impact of a misspecification of the distribution
shape of the residual error is less straightforward. If the
scedasticity is correctly specified but the normality
assumption is not verified, estimation comes back to
extended least squares [7]. Resulting estimators in mixed
effects models may be biased and their uncertainty may not
be appropriate [8]. Simulations using a NLMEM ignoring
skewness will often underestimate variability by simulating
less extreme values.
It is thus important to address potential misspecifications
of the residual error model. Even though elaborate models
have been developed and advocated [3], residual error
modeling is still mostly done on a case-by-case basis using
a limited set of models. Scedasticity could easily be
extended from the commonly used additive, proportional or
combined error models to power models, which include
and expand on the former. Skewness could be addressed
based on an extension of the transform-both-sides (TBS)
approach, in which both the observations and the predic-
tions are transformed so that the resulting residuals on the
transformed scale are normally distributed. An advantage
of the TBS approach is that model parameters are still
estimated on the same scale as when using untransformed
data. The most common TBS approach is the log-trans-
formation, which is used when observations span multiple
orders of magnitude and/or are bound to be positive, such
as for drug concentrations in pharmacokinetic (PK) studies
[9], or when the endpoint relates to a ratio scale, such as
percentage change from baseline for pharmacodynamic
(PD) studies [10]. The log-transformation is actually a
specific case of the Box–Cox power family of transfor-
mations [11], which have been used to describe
chemotherapy-induced myelosuppression in cancer
patients [12] for example. Because a major factor limiting
the use of transformations so far has been that it was
impossible to quantitatively select the best transformation
due to the dependence of the likelihood to the value of the
transformed data, approaches enabling the estimation of the
transformation parameter directly would be an important
asset in RUV modeling. Lastly, the use of distributions
other than the normal distribution has been proposed [13]
but remains underused, notably due to their unavailability
in standard PK–PD software.
We propose that two approaches shall be considered in
order to extend supported scedasticity relationships and
enable objective selection of the distribution shape. The
first approach, referred to as the dynamic TBS (dTBS), is
based on the classical TBS approach but allows both the
shape and the scedasticity parameters to be estimated. The
second approach replaces the assumption of normality of
the residuals by the assumption of a different parametric
distribution. In this paper we investigated the assumption
that the residuals arise from a Student’s t-distribution with
estimated degree of freedom, which allows for heavier tails
than the normal distribution if needed. The aim of the
present work was to investigate the dTBS and t-distribution
approaches using both real data examples and simulations
in order to provide a comprehensive framework for char-
acterization of the residual error model in NLMEM.
Methods
General framework
Let us first describe a general framework for the modeling
of PK–PD data. A generic model for a given set of
observed data Y, which depends on model parameters h and
independent variables x, is defined in Eq. 1. Indexes rela-
tive to individuals, time and/or other independent variables
were omitted for simplification purposes. The variance of
Y according to this model is defined in Eq. 2. Most com-
monly used residual error models are variants of the linear
(i.e., f = 1) slope–intercept model, namely the additive
error model (r2slope ¼ 0), the proportional error model
(r2intercept ¼ 0) and the combined error model (r2slope 6¼ 0
and r2intercept 6¼ 0). However, the power parameter f can
also be estimated [14] to allow for nonlinear
heteroscedastic residual variances.
138 J Pharmacokinet Pharmacodyn (2016) 43:137–151
123
Y ¼ f ðx; hÞ þ f ðx; hÞf  eslope þ eintercept ð1Þ
VarðYÞ ¼ f ðx; hÞ2f  r2slope þ r2intercept ð2Þ
where Y is observed data with variance Var(Y) given the
model, f is a function describing the structural model, x are
independent variables, h are model parameters, f is a power
parameter and eslope and eintercept are assumed independent
with mean 0 and variance r2slope and r
2
intercept; respectively.
The set of parameters which fit a set of data best are
estimated by minimizing minus two times the log-likeli-
hood, also referred to as objective function value (OFV),
which is computed assuming a normal distribution of the
residual error terms (Eq. 3). Minimization of the OFV
leads to ML estimates only if the scedasticity and the
distribution shape of the residual error are correctly spec-
ified, i.e., if Var(Y) is appropriate and the residuals are
normally distributed.
OFV ¼ 2LLY ¼ logðVarðYÞÞ þ ðY  f ðh; xÞÞ
2
VarðYÞ ð3Þ
where -2LLY is minus two times the log-likelihood of the
observed data Y, Var(Y) is the variance of Y given the
model and f(h, x) is the expectation of Y given the model.
dTBS
If the distribution of the residuals appears skewed on the
untransformed scale, ML estimation can still be performed
using the TBS approach. Observations and predictions are
transformed so that residuals, obtained as the differences
between the transformed observations and the transformed
predictions, can be assumed normally distributed. The
Box–Cox transformation (Eq. 4) is a commonly used
transformation to reach this goal, with its shape parameter
k accounting for skewness. A value of k greater than 1
indicates left skewness, while a value of k lower than 1
indicates right skewness. Special cases are a value of 1,
which indicates no skewness, i.e., normally distributed
residuals on the untransformed scale, and a value of 0,
which corresponds to a log-normal distribution. The Box–
Cox transformation can also handle negative observations
by adding a constant to all observations before transfor-
mations to ensure their positivity. Whereas the traditional
TBS approach assumes that the transformed variable has a
constant or homoscedastic variance, we propose to com-
bine the TBS approach with a more flexible power residual
variance model. The resulting dTBS model and its corre-
sponding variance are defined in Eqs. 5 and 6. The power
was chosen to apply to the untransformed prediction. As
will be shown in Eq. 7, the Box–Cox transformation does
not only adjust for skewness but also implies a fixed power
relationship to the untransformed prediction. The estimated
power thus needed to be applied to the untransformed
prediction if one wanted to adjust separately for shape and
scedasticity.
hðX; kÞ ¼ lnðXÞ if k ¼ 0





hðY ; kÞ ¼ hðf ðx; hÞ; kÞ þ f ðx; hÞf  e ð5Þ
VarðhðY ; kÞÞ ¼ f ðx; hÞ2f  r2 ð6Þ
where h is the Box–Cox transformation function, X is a
random variable, k is the shape parameter of the Box–Cox
transformation, f is a power parameter and e are assumed
independent with mean 0 and variance r2.
Structural model parameters estimated using the dTBS
model will have exactly the same interpretation as if no
transformation had been used, which is a major advantage
of this approach. However, parameters related to the
residual error model do not translate directly to the original
untransformed scale. According to Taylor series expansion,
the variance of the untransformed data Y can be approxi-
mated from the variance of the transformed data h(Y, k) as
stated in Eq. 7 and is approximately proportional to the
1 - k ? f power of the model predictions. This is widely
known for log-transformed data, where an additive error on
the transformed scale (k = 0 and f = 0) is approximated
by a proportional error model on the untransformed scale.
From Eq. 7, it is apparent that the shape parameter k does
not only correct for skewness, but also influences scedas-
ticity on the untransformed scale. It is then easily under-
stood than if f is fixed, k will need to adjust both the
scedasticity and the skewness. However it is not guaranteed
that a single value of k can lead to both adequate scedas-
ticity and normally distributed residuals. The addition of a
power parameter is thus truly necessary to be able to
address both aspects. Note that the dTBS model may be
reparameterized using f = k ? d, with d estimated instead
of f in order to decrease the correlation between estimated
dTBS parameters. The dTBS model thus comprises the
additive (k = 1, f = -1), proportional (k = 1, f = 1) and
additive on log (k = 0, f = 0) error models.
VarðYÞ  VarðhðY ; kÞÞ  dhðf ðh; xÞ; kÞ
df ðh; xÞ
 f ðh; xÞ2f  r2  f ðh; xÞ2ð1kÞ
 r2  f ðh; xÞ2ð1kþfÞ ð7Þ
Dynamic estimation of the new error model parameters
k and f needed to be addressed. Whereas no modification
of the ML algorithm as implemented in NONMEM [15] is
required to estimate the power parameter f, a modification
of the procedure is mandatory to estimate the shape
parameter k of the Box–Cox transformation. Indeed, the
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calculated log-likelihood corresponds to the log-likelihood
of the transformed data (Eq. 8). This quantity changes
scale depending on the value of k and thus cannot be used
for parameter estimation when k itself is estimated.
2LLhðY ; kÞ ¼ logðVarðhðY; kÞÞÞ
þ ðhðY; kÞ  hðf ðh; xÞ; kÞÞ
2
VarðhðY ; kÞÞ ð8Þ
Modifying the minimization criterion to reflect the
likelihood of the data on the untransformed scale instead of
the transformed scale enables quantitative comparison
between transformations and thus dynamic estimation of k
[16–18]. The likelihood of the untransformed data can be
calculated from the likelihood of the transformed data
according to the change of variable formula (Eq. 9). The
criteria to use for ML estimation can then be derived
(Eq. 10).
LY ¼ LhðY ; kÞ  dðhðY ; kÞÞ
dY
¼ LhðY ; kÞ  Yk1 ð9Þ
2LLY ¼ 2LLhðY ; kÞ  2ðk 1Þ logðYÞ ð10Þ
Implementation of the dynamic estimation of k was
readily available in NONMEM VI [19] and was adapted
for NONMEM 7 (Bauer, personal communication). The
full dTBS approach with power parameter has been
implemented in PsN [20]. PsN supplies internal files to
modify the likelihood and transform the data on the fly and
adapts the code in the model file to transform the predic-
tions. The user thus only needs to provide a control file
suited for modeling of untransformed data, with residual
variances coded as fixed effect parameters. Further control
of dTBS settings such as initial estimates of k and f is
possible. PsN-supplied files and an example of a modified
control file can be found in Online Resources 1–3.
Student’s t-distribution
Instead of using transformations to obtain normally dis-
tributed residuals, one can change the distributional
assumption itself. In this work we investigated the use of a
Student’s t-distribution, which is a symmetric distribution
defined by its degree of freedom m. The t-distribution
approaches the normal distribution when m tends towards
infinity, and shows heavier and heavier tails as m decreases.
The likelihood of the data when assuming t-distributed
residuals is displayed in Eq. 11 [21]. This approach was
implemented in NONMEM by defining the probability
density function corresponding to a t-distribution in the
control file while using the -2LL option in $ESTIMA-
TION. The gamma function was calculated using the
Nemes approximation [22] (Eq. 12) in NONMEM 7.2 or
using the built-in gamma function GAMLN in NONMEM
7.3. The lower bound for m was set to 3 to guarantee full
definition of the distribution and the upper bound was set to
200 which was considered the m for which the t-distribution
comes back to a normal distribution. An example control





























where LY is the likelihood of the data Y, C is the gamma
function, m is the degree of freedom, f(h, x) is the model
prediction, Var(Y) is the variance of Y given the model and
X is a random variable.
Real data examples
The dTBS and t-distribution approaches were tested sepa-
rately on 10 real data examples [23–31], which comprised
7 PK and 3 PD models. Model complexity varied from
simple one compartment PK models to more complex PD
models and comprised additive, proportional and combined
error models. Fixed log and Box–Cox transformations of
the data were used in three out of 10 models. Eight
examples modeled single endpoints and two examples
modeled two variables simultaneously. Some models had
been developed using the FO method and were adapted to
be run using the FOCEI method. The available data ranged
from sparse to rich, with 2–27 observations per subject. A
summary of the real data examples is given in Table 1.
None of the 10 models used in this work were chosen
because of an indication of skewness in the residual dis-
tribution of the original model; the models using transfor-
mations did however assume skewness on the
untransformed scale.
In the dTBS approach, the Box–Cox and power
parameters were estimated simultaneously using both the
FOCEI and SAEM methods. Estimation of the Box–Cox
parameter alone (assuming an additive RUV model on the
transformed scale) and estimation of the power parameter
alone (keeping the same transformation as in the original
model) were also investigated using the FOCEI method.
For the t-distribution approach, the scedasticity model was
kept identical to the original model and the degree of
freedom was estimated simultaneously to all other model
parameters using the Laplacian method with user-defined
likelihood.
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The impact of the new error models was assessed based
on diagnostic tools commonly used in NLMEM. The
likelihood ratio test (LRT) was used to assess whether the
proposed approaches significantly improved model fit. The
LRT was based on the difference in OFV (DOFV) between
the new and the original error model, which was assumed
to follow a v2 distribution. The degree of freedom of this
distribution was set to the difference in the total number of
estimated model parameters between these two models.
The new strategies were judged to significantly improve
model fit if the absolute value of DOFV was greater than
3.84 for the t-distribution (1 degree of freedom) and
greater than 5.99 for dTBS (2 degrees of freedom).
Parameter estimates and if available their SEs obtained
from the asymptotic covariance matrix were contrasted.
Improvements in fit were also investigated based on plots
of observations versus individual predictions, individual
plots and visual predictive checks. The distribution and
scedasticity of conditional weighted residuals (CWRES),
normalized prediction errors (NPDE) and individual
weighted residuals (IWRES) were analyzed. CWRES and
NPDE are not provided by NONMEM when using user-
supplied likelihood and were obtained by evaluation of the
model and (transformed) data at the final parameter esti-
mates. Further investigations regarding influential indi-
viduals and predictive properties were also undertaken.
Changes in individual OFVs (OFVi) were investigated as
influence diagnostics in order to detect whether most or a
subset of individuals benefited from a given residual error
model structure. Cross-validation techniques using 10
splits of the data (except for the ACTH model, which was
not cross-validated as it contained only seven patients)
were used to assess the predictive performance of the
dTBS approach.
Simulations
Stochastic simulations and estimations (SSEs) were per-
formed in order to investigate the estimation properties of
the new error parameters in terms of bias, precision and
type I error rate. The simulation model was a one-com-
partment disposition, first order absorption and elimination
model displaying either an additive, a proportional or an
additive on log scale error model. Population values used
for simulation were a clearance (CL) of 10 l/h, a volume of
distribution (V) of 100 l and an absorption constant (KA)
of 1/h. The standard deviation (SD) of the IIV was set to
30 % for all three parameters. The RUV was set to 0.2 for
the additive and additive on log models and to 20 % for the
proportional model. The dataset comprised 400 observa-
tions from 50 patients from whom 8 PK samples were
taken 0.25, 0.5, 1, 2, 5, 8, 12 and 24 h after administration
of a single oral dose of 1000 mg. dTBS scenarios were run
using both the FOCEI and SAEM estimation methods
while t-distribution scenarios were run using the Laplace
estimation method. All scenarios were investigated based
on 500 SSE samples.
Software
All fits were performed using NONMEM 7.2 and 7.3 [15]
aided by PsN version 3.5.2 and higher [20]. Graphical
output was generated with RStudio 0.98 using R 3.1.2 and
lower as well as Xpose 4.3.4 and higher [32].
Table 1 Description of the 10 real data examples used to investigate the dTBS and t-distribution approaches
Model Data
type




ACTH/cortisol [23] PD Turnover Combineda – 364 7








Ethambutol [26] PK Oral 2CMT, transit Combined Log 1869 189
Moxonidine PK [27] PK Oral 1CMT Additive Log 1021 74
Moxonidine PD [27] PD Emax Additive Log 1364 97
Paclitaxel [28] PD Transit Additive Box–Cox (k = 0.2) 523 45
Pefloxacin [29] PK IV 1CMT Proportional – 337 74
Phenobarbital [30] PK IV 1CMT Proportional – 155 59
Prazosin [31] PK Oral 1CMT Proportional – 887 64
IV intravenous, CMT compartment, CL clearance
a Additive component fixed
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Results
Real data examples: dTBS
Estimating the Box–Cox and power parameters simulta-
neously led to significant DOFV in comparison to the
original model for all investigated datasets. DOFV were
large, ranging from -243 for the moxonidine PK example
to -7 for the phenobarbital example (Fig. 1). The esti-
mated skewness k ranged from -1 to 2.5 (Table 2). The
estimated power f showed a similar spread. These param-
eters were estimated with good precision when precision
was available, all models displaying low SEs except for
pefloxacin (SE = 0.6) and cladribine (SE = 1). An illus-
tration of the consequence of skewness can be found in
Fig. 2, where simulated distributions of unweighted and
untransformed residuals are compared between the dTBS
and the original models. A comparison of the scedasticity
and the size of the residual error between the dTBS and the
original models can be made based on Fig. 3, which dis-
plays the absolute SD of the residual error over the range of
the observed data for the 12 endpoints of the 10 real data
examples. SDs using the dTBS models were lower than
with the original models in 8 out of 10 cases. At the highest
data point for example, the SD of the RUV using dTBS
ranged between 0.54- and 2.83-fold that of the original
model, with an average value of 1. On a more technical
note, runtimes did not differ much between the original and
dTBS models. Regarding the influence of the estimation
method, skewness estimates obtained with FOCEI and
SAEM were close except for the paclitaxel and pefloxacin
models. In these examples, SAEM k estimates confirmed
the direction of the skewness found using FOCEI but
indicated a higher degree of skewness (k = -0.6 vs. 0.15
for paclitaxel, k = -1 vs. -0.79 for pefloxacin).
Approximated power on the untransformed scale stayed
similar between the two estimation methods. Estimating
both dTBS parameters simultaneously was significantly
better than estimating only one of them for all models
except phenobarbital. DOFV were significant for 6 out of
10 models when only the Box–Cox parameter or the power
parameter were estimated. Only two examples (cladribine
and cyclophosphamide/metabolite) displayed a worse
model fit than with the original model when estimating a
single power parameter, which was related to the fact that
they were originally modelled with combined error models.
Estimates of k obtained using a fixed additive error model
on the transformed scale differed from those obtained using
Fig. 1 Differences in OFV (DOFV) between the original and the
dTBS, Box–Cox, power and t-distribution models for the 10 real data
examples. The dashed lines indicate the threshold for significant
improvement over the original error model given the appropriate
degree of freedom
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dTBS. However, the direction of the estimated skewness
stayed identical except for moxonidine PK and prazosin,
whose estimated k values indicated left-skewness using
dTBS but right-skewness using the Box–Cox alone. The
estimated power f also differed depending on whether it
was estimated alone or together with k. For most models,
these changes however translated into similar scedasticity,
as evidenced by small differences between approximated
powers on the untransformed scale when using the dTBS,
Box–Cox and power error models (Online Resource 5).
These results confirmed that only the combined approach
could correct simultaneously for skewness and scedasticity
and thus the Box–Cox or power error models alone were
not further investigated in this work.
Estimates of non-residual error model parameters and
related precision using the dTBS approach differed from
those obtained using the original models in a number of
cases. Table 3 presents examples of such changes. Some
models presented changes in both selected fixed effects and
random effects variances, some presented changes only in
random effects and others displayed no changes at all in
population parameters. Changes in parameter estimates
were deemed physiologically plausible based on the
available insight on the model and data. dTBS also
impacted the precision of parameter estimates, which could
be improved or deteriorated depending on the model and
parameter.
Changes in plots of observations versus individual pre-
dictions, individual plots and visual predictive checks were
typically minor (data not shown). Residual distributions of
CWRES, NPDE and IWRES showed some improvement
for examples with high DOFV such as moxonidine PK,
ethambutol and prazosin (Fig. 4) but little difference in
other cases.
Real data examples: Student’s t-distribution
Using a t-distribution with estimated degrees of freedom
led to significant improvement in DOFV for five out of
the seven models for which the estimation of the degree
of freedom was successful. The cyclophosphamide/
metabolite and phenobarbital examples did not benefit
from t-distributed residuals (Fig. 1; Table 2). When sig-
nificant, DOFV were large, ranging from -400 for the
moxonidine PK example to -20 for the pefloxacin
example. Estimated m values spanned the entire range of
possible m values (from m = 3 to 200) with point estimates
between 3 and 9 for significantly improved models
(Table 2). The moxonidine PK, prazosin and ACTH/cor-
tisol examples showed the heaviest tails, whereas the







k (SE) f (SE) Approximated
scedasticity
1 - k ? f
DOFV m DOFV
ACTH/cortisol [23] Combineda 2.9 0 (–) 0.68 (0.27) 1.68 -86 3 -28
0 (–) -0.47 (0.18) 0.53
Cladribine [24] Combined 15.8 -0.65 (1.2) -0.92 (1.0) -0.58 -20 5 -36c
Cyclophosphamide/
metabolite [25]
Additive (parent) 5.4 0.85 (–) 0 (–) 0.15 -8.6 9 -2.6
Combined (metabolite) 0.86 (–) 0 (–) 0.16
Ethambutol [26] Combined on log 11.8 0.67 (0.21) 0.67 (0.16) 1 -43 3 -100c
Moxonidine PK [27] Additive on log 11.6 1.5 (0.066) 1.6 (0.076) 1.1 -243 3 -400
Moxonidine PD [27] Additive on log 11.4 -0.93 (–) -1.1 (–) 0.84 -14 9 -25
Paclitaxel [28] Additive on Box–Cox 19.3 0.15 (–) -0.25 (–) 0.6 -22 3 -7.4c
Pefloxacin [29] Proportional 23.2 -0.79 (0.61) -1.2 (0.58) 0.59 -21 4.7 -20
Phenobarbital [30] Proportional 28.9 1.8 (0.44) 0.83 (0.23) 0.03 -7 ? 0
Prazosin [31] Proportional 11.2 2.4 (0.17) 2.5 (0.16) 1.1 -100 3 -169
a Additive component fixed
b Presented dTBS results are those obtained with the FOCEI method
c Standard estimation of m impossible, estimated through likelihood profiling
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estimated degree of freedom in the phenobarbital example
pointed toward normally distributed residuals. Asymptotic
SEs on m could not be estimated either because of model
instability or because m was estimated at its upper or
lower boundary. It should be noted that the use of the
Laplacian method in NONMEM (instead of the FO or
FOCE methods on which the models were originally
developed) often led to minimization problems and a
failure of the covariance step, and this regardless of which
distribution was used. In the cladribine, ethambutol and
paclitaxel examples, m stayed around any given initial
guesses but changes in OFV were nevertheless observed
when fixing m to different values. Models for which
estimation of m was not possible will not be discussed
here.
As with the dTBS approach, physiologically plausible
changes in estimates of non-residual error model parame-
ters using the t-distribution approach were observed
(Table 3). Individual predictions in the moxonidine
example evidenced a better agreement to the observations
by being further away from a limited number of outliers.
Consequences of changes in estimated parameters on
individual predictions were less apparent for the other
examples. As observed with the dTBS approach, changes
in the agreement between observed and expected residual
distributions could be observed (Fig. 5) for some but not all
models.
Simulations: dTBS
Simulated additive, proportional and additive on log error
models could be re-estimated using dTBS (Table 4). k
estimates were unbiased with the additive on log error
model error model but showed downward bias of 0.13 and
0.26 for the additive and proportional error models. Using
SAEM instead of FOCEI removed the bias on k for the
proportional error model. Estimates of d (f was reparam-
eterized in the simulation exercise) were unbiased even in
the presence of bias in k. The SEs of dTBS parameters
were small (below 0.25) for the proportional and additive
on log models. Precision on k was poor (SE = 0.73) for the
additive model. Type I error was controlled at the inves-
tigated dataset size for the additive and additive on log
error models when using FOCEI and for the proportional
error model when using SAEM. Other model parameter
estimates and related precision were similar whether dTBS
parameters were estimated or fixed to their true values.
Simulations: t-distribution
Additive, proportional and additive on log scale error
models simulated under the normality assumption could be
re-estimated using the t-distribution. The estimates of the
degrees of freedom tended towards the given upper bound
Fig. 2 Simulated residual error
distributions on the
untransformed scale for the
original and dTBS error models
for the 12 endpoints of the 10
real data examples. Dotted lines
correspond to the original error
model and full lines to the dTBS
error model. These distributions
were obtained through
simulations using the final
dTBS/original estimates. The
standard deviations of the
distributions were calculated
based on the medians of the
observed data
144 J Pharmacokinet Pharmacodyn (2016) 43:137–151
123
of 200. Type I error was close to 0 % for all simulated error
models.
Discussion
Implementation of both the dTBS and the t-distribution
approaches in NONMEM was successful apart from sta-
bility issues related to the use of the Laplacian method with
some of the investigated models. The additional error
parameters could be estimated using ML and OFV could be
compared to select the most appropriate model. The new
error models improved model fit for the investigated real
data examples.
Real data examples: dTBS
Significant OFV drops were observed for all models when
allowing for skewness in the residual error. OFV was
expected to be sensitive to changes in the residual error,
and power to detect such changes is expected to be high as
all observations contribute to the determination of the
residual error model.
Point estimates of k indicated some degree of skewness
in the distribution of the residuals for all models. Absence
of skewness could not be excluded for the phenobarbital
and cladribine examples, for which asymptotic 95 % con-
fidence intervals on k included the reference value of 1.
The estimated shape parameter indicated right-skewed
residuals (i.e., higher positive than negative residuals) on
the untransformed scale for 7 out of 10 models. This is in
line with the type of data used here, where the presence of
left-censoring as a result of the impossibility to observe
negative endpoint values often leads to right-skewness of
the residuals. Two PK examples with rich sampling
showed left-skewness (moxonidine PK and prazosin) pos-
sibly as a consequence of absorption model misspecifica-
tions. Box–Cox estimates for variables which were
simultaneously modeled (ACTH/cortisol and cyclophos-
phamide/metabolite) stayed similar, which was not
Fig. 3 Standard deviation of the residual error variance as a function of the observed data for the original and dTBS error models for the 12
endpoints of the 10 real data examples. Dotted lines correspond to the original error model and full lines to the dTBS error model
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unexpected since both profiles and assays were homoge-
nous in the studied cases.
The shape parameter k differed greatly depending on
whether the power parameter f was estimated or fixed to 0
as in the traditional TBS approach. This could be explained
by the fact that in the latter case, k determines not only the
skewness but also the scedasticity, which is then equal to
the power of (1 - k). It appeared that estimating k alone
was correcting for scedasticity more than for skewness,
which makes sense as scedasticity is expected to have a
much higher impact on model fit than skewness. This was
best illustrated in the paclitaxel example, originally mod-
elled with a Box–Cox transformation of 0.2 corresponding
to a scedasticity of 0.8 on the untransformed scale
(k = 0.2, d = 0.8). Using dTBS, both the right-skewness
and the lower than proportional scedasticity were con-
firmed but were free to take on slightly lower values
(k = 0.15, d = 0.6). It follows that to correct for both
skewness and scedasticity, one should use the full dTBS
approach and not the Box–Cox transformation alone.
Regarding the value of k itself, skewness is most likely
multifactorial and depends on a mixture of endpoint type
(presence of physiological boundaries for example), study
design (inclusion/exclusion criteria), assay characteristics,
and model misspecification. Identification and categoriza-
tion of causes leading to the presence of skewed residuals
by data and/or model types is not straightforward and as
such it will be difficult to anticipate the likely value of k in
a given setting.
The approximated power on the untransformed scale
was estimated to be proportional (four models), close to
additive (two models) or somewhere in between (three
models). The ACTH/cortisol model showed the highest
scedasticity, with an error approximately proportional to
the square of the ACTH predictions, which may be
explained by the dichotomous nature of this endpoint, with
a cluster of values very close to 5 and the other above 15.
There was no clear trend between original and dTBS
scedasticity, with some models keeping their original
scedasticity (moxonidine PK and PD, prazosin) and others
differing. Phenobarbital was however the only model for
which the additive error model was found to fit the data
better than the original proportional model. This had been
concluded previously [33] and is to relate to the small data
Table 3 Selected examples of changes in non-residual error model parameters when the dTBS and the t-distribution approaches are used
Model Changes in non-residual error model parameters with dTBS Changes in non-residual error model parameters
with the t-distribution
ACTH/cortisol [23] 4-fold decrease in surge amplitude
1.5-fold increase in maximum effect
2-fold increase in concentration leading to half the maximum
effect
2-fold decrease in Hill coefficient
25 % reduction in surge amplitude
Modification of the models parameters related to the
Emax function
Cladribine [24] Unchanged estimates
Higher RSE
15 % decrease in inter-compartmental clearance
50 % increase in IIV of volume of distribution
Cyclophosphamide/
metabolite [25]
Ratio between induced and non-induced clearance decreases
from 5 to 1
1.5-fold increase in maximum effect
Limited changes in estimatesa
Ethambutol [26] 20–30 % change in volumes of distribution, mean transit time,
absorption rate and related IIV
20–30 % change in volumes of distribution, mean
transit time, absorption rate and all IIV
Moxonidine PK [27] 1.2-fold increase in IOV of absorption rate
0.8-fold decrease in IIV of absorption rate
3-fold decrease in IIV of absorption rate
Moxonidine PD [27] 1.5-fold increase of maximum effect
0.3-fold decrease in transfer rate constant to the effect
compartment
1.3-fold increase in transfer rate constant to the
effect compartment
Phenobarbital [30] IIV of clearance increased from 33 to 44 %, lower uncertainty
(RSE 22 vs. 63 %)
no change as m = ?
Pefloxacin [29] IOV of volume decreased from 9 to 4.7 %, higher uncertainty
(RSE 97 vs. 42 %)
Unchanged estimates
Prazosin [31] Unchanged estimates
Unchanged RSE
50 % increase in covariate effect of race on
clearance
IIV inter-individual variability, IOV inter-occasion variability, RSE relative standard error
a Not discussed since standard estimation of m impossible, see ‘‘Results’’ section for the t-distribution
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range investigated, which confounds the discrimination
between additive and proportional error models. A constant
variance, or even a second power term, could in theory be
added to the dTBS model. However, while combined error
models make sense on the untransformed scale, they
translate into ‘‘double’’ power models when used in com-
bination with a transformation, which may be both hard to
estimate and to interpret. In addition, it was believed that
the combination of power and Box–Cox would be flexible
enough to describe observed residual error patterns, which
was supported by the fact that the addition of a second f
term for the combined error models did not improve model
fit (data not shown).
As already observed for individual parameter distribu-
tions [34], better agreement of the distribution of residuals
to the normality assumption was difficult to assess visually.
The observed IWRES distributions could be confounded by
the presence of high e-shrinkage (mostly between 10 and
15 % but up to 20–30 % for paclitaxel, pefloxacin and
phenobarbital), which renders the interpretation this diag-
nostic subject to caution. Other residuals such as CWRES
and NPDE, which are not sensitive to shrinkage, were
available. However, these metrics are affected by all ran-
dom effects of the model (IIV, IOV and RUV) and thus are
less specific to the residual error. These observations
highlight limitations of standard residual error diagnostics
in NLMEM.
Visualizing the impact of changes in other model
parameter estimates in order to diagnose the RUV model
did not prove more supportive than residual diagnostics,
which was not unexpected since the impact of changes in
the RUV model should be minor compared to changes in
the structural model. However, estimating dTBS error
parameters could lead to changes at all levels of NLMEM:
estimates of fixed and random effects as well as related
precision. Part of the difficulty in interpretation is due to
the interaction between the different levels of variability in
NLMEM.
Limitations of commonly used goodness-of-fit diag-
nostics drew focus on the OFV as the main criterion to
indicate improvement of the residual error model. To
complement this criterion, additional investigations using
influence diagnostics and predictive properties were con-
ducted in this work. Changes in individual OFV were used
to investigate the influence of individuals on dTBS
parameters (Online Resource 6). The dTBS approach
always benefitted the majority of individuals in a given
dataset, with an average proportion of individuals
improved of 64 % (range [51–100 %]) over the 10 models.
The size of the overall OFV drop was related to the number
Fig. 4 CWRES, NPDE and IWRES QQ-plots for the original and dTBS error models in the prazosin example. Dark circles correspond to the
final dTBS model, light circles to the original model. Sample quantiles are compared to the theoretical quantiles of a standard normal distribution
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of individuals who benefited from dTBS, the highest
DOFVs being observed in examples for which dTBS was
highly beneficial for many individuals. The proportion of
individuals responsible for the significant part of the DOFV
was 14 % on average. This may appear low, but it is
important to note that the very nature of distributions such
as the Box–Cox predisposes it to individual influence, as
only a limited part of the distribution really deviates from a
normal distribution. The superiority of the dTBS model
when taking all individuals into account was confirmed by
better predictive properties as assessed through cross-
validation. The OFV sum over cross-validation datasets
was lower with dTBS than with the original models for all
examples except cladribine and pefloxacin, and dTBS
parameter estimates were consistent between training
datasets (data not shown). The two examples that showed
worse predictive properties and inconsistent estimates
(k = -1.6 instead of -0.7 for cladribine, k = 2 instead of
-0.8 for pefloxacin) also displayed high SEs on dTBS
parameters, which would discourage the use of the dTBS
error model. To summarize, this indicated that accounting
for deviations, even if they are small and localized, is
Fig. 5 CWRES, NPDE and IWRES QQ-plots for the original and
t-distributed error models in the prazosin example. Dark circles
correspond to the final t-distribution model, light circles to the
original model. Sample quantiles are compared to the theoretical
quantiles of a standard normal distribution for the original model and
to that of a standard normal distribution (NPDE) or a t-distribution
with 3 degrees of freedom (CWRES, IWRES) for the t-distributed
error model
Table 4 Estimated bias, precision and type I error rates for the dTBS error model and type I error rates for the t-distribution error model in the
simulation examples (500 SSE samples)
Error models Estimation methods dTBS t-Distribution
True k True d Bias k Bias d SD k SD d Type I error (%) Type I error (%)
Additive FOCEI 1 -1 -0.13 -0.084 0.73 0.10 2.00 0
Proportional FOCEI 1 0 -0.26 -0.020 0.26 0.088 11.20 0
Proportional SAEM 1 0 -0.036 0.033 0.31 0.092 4.40 –
Additive on log FOCEI 0 0 -0.022 0.0066 0.24 0.087 3.60 0.20
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beneficial on the group level, and it is known that a limited
number of outliers can overwhelm ML estimation [16]. The
investigation of influential individuals also confirmed the
interaction between the different levels of variability in
NLMEM. Indeed, the individuals who supported most of
the DOFV were the ones displaying the greatest changes in
empirical Bayes estimates, as seen in the cladribine,
cyclophosphamide/metabolite and ethambutol examples.
Note that individual influence was less marked for the
power parameter, which by definition has a smaller ten-
dency of being outlier-driven. The inclusion of an esti-
mated power of the mean error parameter was shown to be
robust to the skewness model, with the approximated
power on the untransformed scale staying fairly constant
over various values of the shape parameter. The incorpo-
ration of IIV on error parameters was not considered here
but could be envisaged if the number of observations per
individual is high enough for this to be estimable.
Real data examples: t-distribution
The 10 investigated real data examples benefitted from
various degrees of heavy tails. Examples with highest
DOFV often had an estimated degree of freedom of 3, and
all models showing a significant improvement had a m
below 10. As with the dTBS approach, reasons to observe
heavy tails in the distribution of the data are most likely
multifactorial, and the anticipation of the value of m in a
given setting is difficult.
Residual diagnostics faced the same limitations as with
dTBS, namely the lack of specificity and the sensitivity to
e-shrinkage. Changes in residual plots were not always
visible but in general more pronounced than with dTBS.
This could be expected as the t-distribution allows more
extreme residuals (and this more frequently) than the Box–
Cox transformation. Changes in goodness-of-fit plots based
on individual predictions were also not always straight-
forward to detect, but in some cases such as moxonidine
PK an overall better agreement was seen at the cost of few
outlying data points.
Individual influence was also investigated for the t-dis-
tribution, even if it was not unexpected when using such
distributions. The conveyed picture was similar to that
observed with the dTBS approach. The average proportion
of individuals improved when the t-distribution lead to a
significant DOFV was 71 % (range [51–86 %]) over five
models, with a proportion of individuals responsible for the
significant part of the DOFV of 29 % on average. Predic-
tive properties using cross-validation were not investigated
for the t-distribution due to the instability of the investi-
gated models with the Laplacian method.
The incorporation of IIV in RUV, either as a continuous
distribution [35] or a mixture model with two different
residual error variances allowing an estimated fraction of
the individuals to display higher RUV than the rest of the
individuals, was not investigated here but could also be
considered. Other distributions could also be considered:
mixture models at the observation level, power exponential
models, Cauchy, Laplace, Gamma and Weibull have pre-
viously been used in the PK literature [13, 36] and have
shown improvement over the normality assumption. It
should be noted that current implementation using the
Laplacian method proved limiting in this case, as it led to
minimization difficulties for both the normal and Student’s
probability distribution functions in about half of the
models. This should be addressed to guarantee efficient use
of the t-distribution and potentially other distributions.
Simulation examples
The design investigated here presented rich sampling at the
individual level but a moderate number of total observa-
tions as compared to the real data examples. The down-
ward bias of -25 % in k despite low SE led to a doubling
of the type I error with the FOCEI method when an
interaction between predictions and residuals was present.
This was corrected when using the SAEM method, hinting
towards limitations of the FOCEI method in the presence
of scedasticity and high nonlinearity. Bias of -10 % on k
in the additive model did not lead to an increase in type I
error, probably due to the high SE observed for this
parameter. Part of this bias could be linked to the censoring
of negative concentrations (around 1 % of simulated con-
centrations per dataset), which may have induced some
right-skewness in the simulated data. The high uncertainty
on k could be linked to the relatively low variance used for
this model, as SE on k decreased to levels similar to those
observed for the proportional and additive on log models
when residual variance was increased (data not shown).
Estimates and precision of parameters not related to the
residual error were consistent across all error models in the
simulated settings.
Comparison of dTBS and t-distribution approaches
Interestingly, dTBS and t-distribution DOFV were often
similar and real data examples truly benefitting from the
two approaches were the same. This could at first seem
counterintuitive as the two error models have conflicting
assumptions regarding the presence of skewness. However,
the dTBS and t-distribution approaches are similar in that
they both allow some individual predictions to be further
away from the observations. The difference lies in the
balance (t-distribution) or the mismatch (dTBS) between
the numbers of positive and negative high residuals, thus
the presence or absence of skewness. One can easily
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imagine that if uni- or bilateral outlier observations are
present, an approach that allows some type of outliers will
be beneficial even if the symmetry is misspecified. Another
difference between the two approaches lies in the number
of outlying residuals they allow, and more generally where
the mass of the residuals is expected to be. For example, a
t-distribution with m = 3 allows 14.5 % of the residuals to
have an absolute value greater than 1.96, compared to
2.8 % with a dTBS distribution with k = 2 and 5 % for the
normal distribution, given a SD of 1 for all. Models with
more extreme outliers may thus benefit from a t-distribu-
tion more than they do from dTBS even if these outliers are
not symmetric, as was seen in the moxonidine PK and
prazosin examples. Overall, both approaches have the
advantage of being capable of handling potential outliers
while avoiding subjective predefined exclusion criteria or
case-by-case handling of outlying data points. It can also
be noted that both approaches, in particular the t-distribu-
tion, address kurtosis and can thus correct both for peaked
and/or heavy-tailed distributions. When using these
approaches, one naturally needs to ensure the absence of
trends in the estimated skewness or outlying data points to
avoid any masking of potential model misspecification by
the residual error model, particularly during model build-
ing. However, once a model is deemed as good as it can be,
handling often inevitable remaining model misspecification
through the use of one of the proposed approaches is more
indicated than simply ignoring it. The two approaches
could also be combined, allowing for both heavy tails and
skewness. This would also permit to treat dTBS and the
t-distribution as nested models and thus to select the most
beneficial one based on truly comparable DOFV. This was
done using the prazosin example (model code provided in
Online Resource 7). In this example, no skewness was
detected when estimating m, k and f simultaneously, con-
firming that the t-distribution was more beneficial. How-
ever, as for any component of a model, any added
complexity always needs to be balanced with potential
gains, which may be more limited for the residual error
than for other components of the model.
How to proceed in practice
When to use the proposed approaches is naturally a rele-
vant question. The choice between these approaches can be
guided by the presence or absence of skewness in the
residual distribution. If a final model is obtained through
traditional model building, it is recommended to apply
dTBS and/or t-distributions as a mean to improve the
robustness of conclusions drawn from the model. However,
these approaches could also be introduced earlier in the
model building, when choices between error models are
usually made and when diagnostics indicate deviations
from standard residual error assumptions. If they appear
beneficial, they should be retained. If possible, RUV
parameters should not be fixed during model building to
maintain flexibility with regards to changes in other, more
important parts of the model.
Conclusion
The dTBS and Student’s t-distribution approaches are two
approaches capable of addressing non-normal residuals.
The dTBS approach is able to adjust both skewness and
scedasticity while the t-distribution allows for symmetric
heavy tails in the residual distribution. Both approaches can
be combined in a general and flexible framework which
addresses the trial-and-error strategy usually employed for
residual error model building. While getting the statistical
model right is not a primary aim, it is believed that scrutiny
towards residual error assumptions will enhance the quality
of model-based analysis and any subsequent simulations.
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